HILPDA-mediated lipidomic remodelling promotes radiotherapy resistance in nasopharyngeal carcinoma by accelerating mitophagy

• DOI: 10.1007/s00018-023-04891-9
• Publication Date: 2023-08-08T04:01:35Z
• Authors: Yue Zhang; Chen Pang; Chi Zhang; Yijie Wang; Peng Wang; Yanrong Chen; Junyi Wang; Ying Hu; Chengxiang Liu; Houjie Liang; Ganfeng Xie; Juanjuan Ou
• Keywords: Gene Expression Regulation, Neoplastic; Nasopharyngeal Carcinoma; Cell Line, Tumor; Lipidomics; Mitophagy; Humans; Nasopharyngeal Neoplasms; 3. Good health; Neoplasm Proteins

Radiotherapy resistance is a major obstacle to nasopharyngeal carcinoma (NPC) therapy and contributes to tumour recurrence and metastasis. Lipid metabolism is a key regulatory mechanism in cancer biology; however, its role in NPC radiotherapy resistance remains unclear. In this study, we identified hypoxia-inducible lipid droplet-associated protein (HILPDA) as a newly discovered regulator of radioresistance that induces not only lipid droplet (LD) formation but also intracellular lipid remodelling, notably changing mitochondrial cardiolipin (CL) levels. Additionally, we found that the upregulation of CL promotes mitophagy in response to irradiation exposure. Mechanistically, HILPDA inhibits PINK1-mediated CLS1 ubiquitination and degradation. The combination of a mitophagy inhibitor and irradiation significantly increases the radiosensitivity of NPC cells. Human cancer-derived data confirmed that the HILPDA-CLS1 pathway promotes NPC radioresistance. Collectively, these findings suggest that HILPDA plays a critical role in promoting NPC radioresistance and might be targeted to overcome radiotherapeutic resistance in NPC patients in the clinic.